Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis
Open Access
- 26 July 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (10) , 1809-1813
Abstract
Objectives. There is a known association of imbalanced peripheral tolerance and autoimmune diseases. The binding of programmed cell death 1 (PD-1) with its ligands 1 and 2 (PD-L1 and PD-L2) inhibits T-cell proliferation through a negative signal via recruitment of src homology 2-domain-containing tyrosine phosphatase 2. Therefore we evaluated the effect of the PD-1, PD-L1 and PD-L2 genotypes on the occurrence of AS in a population of Taiwanese patients. Methods. Genetic polymorphisms of PD-1 G-536A, PD-L1 A8923C and PD-L2 C47103T were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for 330 AS patients and 330 healthy controls who were matched by age and gender. Results. Subjects with the PD-1 GG genotype [matched relative risk (RRm) 1.78; 95% CI 1.13, 2.81] and the GA genotype (RRm 1.59; 95% CI 1.09, 2.31) had significantly greater risk for AS than those with the AA genotype. Subjects with the PD-L2 CT genotype had lower risk for AS than those with the CC genotype (RRm 0.01; 95% CI 0.001, 0.06). Interestingly, the combined genotypes of PD-1 G-536A, PD-L1 A8923C and PD-L2 C47103T also appear to be associated with AS development. Conclusions. Our results suggest that PD-1 G-536A, PD-L1 A8923C and PD-L2 C47103T polymorphisms are associated with the presence of AS.Keywords
This publication has 25 references indexed in Scilit:
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease?Nature Clinical Practice Rheumatology, 2006
- Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitisArthritis Research & Therapy, 2003
- Ankylosing spondylitis: an overviewAnnals of the Rheumatic Diseases, 2002
- Genetic aspects of ankylosing spondylitisBest Practice & Research Clinical Rheumatology, 2002
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Circulating cytotoxic CD8+ CD28- T cells in ankylosing spondylitisArthritis Research & Therapy, 2001
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- ANKYLOSING SPONDYLITIS AND HL-A 27The Lancet, 1973